PENN PSYCHIATRY NEWSLETTER
January / February 2020

Vision
Promoting health for the brain and mind to transform lives and the world.

Mission
Penn Psychiatry develops and implements new ideas to understand, prevent, and treat disorders of the brain and mind, through innovative research and discoveries, outstanding educational programs, world renowned clinical services, and transformational public health policies.
Penn Psychiatry Collaborates

For this month’s newsletter, I wanted to highlight the ways in which Penn Psychiatry has forged alliances to improve health across a variety of domains. The collaborations are both local and national and range from genomics to public policy. So exciting to see!

**Andrew Strasser and the Tobacco Center of Regulatory Science on “Examining the Effects of Advertising, Packaging and Labeling on Perceptions, Use and Exposure of Combustible Tobacco Products.”**

An outstanding example of collaboration is Andrew Strasser’s Tobacco Center of Regulatory Science (TCORS) for which he partnered with Cristine Delnevo and colleagues from Rutgers University. The Center is funded by a U54 grant from the US Food and Drug Administration and National Cancer Institute: “Examining the Effects of Advertising, Packaging and Labeling on Perceptions, Use and Exposure of Combustible Tobacco Products.” The center, awarded in September 2018, examines the effects of advertising, packaging and labeling on perceptions, use and exposure of combustible tobacco products. The investigators are conducting 4 highly integrated R01-level projects to accumulate a comprehensive and rigorous body of knowledge on the effects of tobacco communication on regulatory-relevant outcomes of risk perception, use, behavior and exposure for combustible tobacco products. In addition, the center has a biosample analytic and regulatory core and a tobacco industry marketing core to support projects within the center and as a service to external collaborators. A career enhancement core, led by Janet Audrain-McGovern (Psychiatry), supports pre- and post-doctoral fellows and mid-career investigators. Other Penn colleagues include Melissa Mercincavage (Psychiatry), Joseph Cappella (Annenberg), and Eric Feldman (Law), as well as investigators at Columbia, Georgetown, and Wake Forest Cancer Center.

**David Mandell and Kyle Kampman partner with Hillary Bogner of Family Medicine on “Opioid Use Disorder and Mental Health Conditions.”**

A key goal of the department is to bring research and the clinic closer together, conducting work that is clinically relevant in the short term. To this end, Psychiatry has joined forces with Family Medicine to undertake an ambitious research project: The Whole Health Study: Collaborative Care for Opioid Use Disorder and Mental Health Conditions. Principal investigators David Mandell, Hillary Bogner and Kyle Kampman have launched a study that will test a collaborative care model for patients with opioid use disorder (OUD) and major depression, post-traumatic stress disorder, or an anxiety disorder in primary care. The investigators also will examine clinician and practice characteristics associated with successful implementation, and the cost effectiveness of different care models. Ultimately, this study will provide definitive evidence regarding the most parsimonious set of elements of integrated collaborative care required to maximize outcomes for patients with OUD and psychiatric disorders. The investigators will partner with Penn primary care practices, including several Penn Integrates Care practices, as well as Federally Qualified Health Centers and District Health Centers. The study is in early stages, finalizing measures, developing the clinical training manual, and recruiting practices. The team anticipates recruiting its first participants in September of 2020.
Raquel Gur and 9 Universities on “Dissecting the effects of genomic variants on neurobehavioral dimensions in CNVs enriched for neuropsychiatric disorders.”

On the translational science front, Raquel Gur is leading 9 universities in a U01 funded, innovative large-scale collaborative study focused on neuropsychiatric manifestations of Rare Genetic Disorders (RGDs), which often evince negative effects on brain development and functioning throughout the lifespan. Because copy number variants (CNVs) at 22q11.2 and 16p11.2 loci are among the most common RGDs impacting developmental psychopathology, this far-ranging scientific team of investigators in North America and Europe will capitalize on highly informative samples and integrate prospective dimensional and categorical phenotyping with whole genome sequencing across these reciprocal CNVs. The goal is to identify convergent risk mechanisms for developmental neuropsychiatric disorders that have relevance to the broader population. The effort builds on established collaborations between Penn and CHOP in the study of 22q11.2 that led to a previously funded international consortium that now expands to other CNVs.

Hank Kranzler and Bob Mach of Radiology establish the “Penn Pet Addiction Center of Excellence (Penn Pace)”.

Exemplifying molecular approaches to studying addictions, Hank Kranzler and Bob Mach have a P30 grant from NIDA, to support the cutting-edge Penn PACE, which combines the department’s established strengths in clinical research on opioid use disorder with the technical expertise of the PET program at the University of Pennsylvania and the PET neuroimaging program at Yale University. Together, these outstanding resources will yield mechanism-level discoveries that are critical for translation of basic addiction science to the clinical care of patients suffering from OUD. This translation promises to substantially improve treatment outcomes for OUD and associated disorders, reducing the high rates of morbidity and mortality associated with them. One initial study at Penn examines the individual and joint effects of OUD and HIV infection on brain inflammation using a novel inflammatory radioligand. Another study evaluates the impact of polygenic risk scores derived from a large genome-wide association meta-analysis of OUD on mu-opioid receptor binding potential measured with carfentanil. Initial studies at Yale are comparing the performance of neuroinflammation radioligands in a non-human primate model and the impact on mu-opioid receptor binding potential of a genetic variant associated with usual methadone dose.

I am delighted to have such ground-breaking diverse large research grants led by our faculty and leveraging the rich intellectual life at Penn and beyond.
Grants

Cesar de la Fuente-Nunez, American Institute of Chemical Engineers, Autonomous Generation of Computer-Made Antibiotics, $75,000.

Gregory Corder, Brain & Behavior Research Foundation, Elucidating the Neurodevelopmental Disabilities Associated with Neonatal Opioid Withdrawal, $70,000.

In The News

Psychiatric News, Innovative Program Provides MH Care to Thousands, By Cecilia Livesey and Courtney Benjamin Wolk - Mental health and substance use disorders are a leading cause of disease burden in the United States and a major driver of health care costs. Most people who get mental health care do so through primary care, and less than half of those referred to specialty psychiatric care follow through. Read more from Cecilia Livesey and Courtney Benjamin Wolk here.

Rinad Beidas crowdsourced books for women on Twitter. Then Penn Nursing Librarian, Richard James, created a collection in the Penn Library catalog that includes the majority of the books in e-book format. Read more here.

Journal Articles

The Journal of Clinical Psychiatry, Impact of Pharmacogenomics on clinical Outcomes for Patients Taking Medications with Gene-Drug Interactions in a Randomized Controlled Trial, by Michael Thase et al - For patients with major depressive disorder (MDD), the standard treatment approach includes prescribing based on a clinician’s preference and experience as well as patients’ past treatment histories. Read the article here.
Quotes

Dave Oslin was quoted in U.S. Medicine about the potential impact of pharmacogenetic testing in September. Read the article here.

Philip Gehrman was quoted in a December story in Texas Medical Center’s Pulse about sleep apnea and a nerve-stimulating implant device for central sleep apnea that VA recently began using in treatment. Read the article here.

Awards

Tami Benton was selected by the SOBP Awards Committee as the recipient of the Society’s 2020 Humanitarian award. This Award recognizes those who have demonstrated service and advocacy for mental illness.

Tami Benton was selected as the recipient of the 2020 Virginia Q. Anthony Outstanding Woman Leader Award to honor her exemplary career as a leader in the field of child and adolescent psychiatry.

Cesar de la Fuente received the Kavli Foundation Emerging Leader in Chemistry Award.

David Weiss received the Scott Mackler Award for Excellence in Substance Abuse Training.

Albert Yu received the Dean’s Award for Excellence in Clinical Teaching by House Staff.
Jacqueline Hudak received the Dean’s Award for Excellence in Medical Student Teaching by an Allied Health Professional.

Kristin Leight received the Dean’s Award in Excellence in Clinical Teaching at an Affiliated Hospital.

Special Mention

Jessica Shaw, a postdoctoral fellow was selected for the ITMAT Certificate Program in Translational Science and was also provided a slot in the CTSA TL1 training grant.

Jenny Wang, a Psychiatry resident has been invited to become a member of the 2020 – 2022 Health care Leadership in Quality Residency Track (HLQ) given her interest in improving quality within Penn Medicine.

Philip Campbell has been selected to participate in the 2020 Research during the 2020 APA Annual Meeting.
Events

AFSP
SAVE A LIFE GALA 2020
MARCH 13, 2020 • 7 PM
Cocktails, Dinner & Dessert
SILENT AUCTION • DJ

231 S. Broad Street
Philadelphia, PA 19107

2020 HONOREES
THE SURVIVOR OF THE YEAR AWARD
JES AND GENNETTE SMITH
THE SHELLEY LEAFHART-WILLIAMS
COMMUNITY OUTREACH AWARD
THE LUCY

LIFESAVER OF THE YEAR
THE HARRIS AND LOUISE KUBIKAWA MEDAL

For tickets visit: afsp.org/phillygala
For more information, contact: lyndseynyackel@afsp.org

LIFESPAN BRAIN INSTITUTE
LiBl Seminar
Dissecting Phenotypic Variation in Response to Trauma Using Systems Biology
February 19, 2020, 1:30 pm to 2:30 pm
Leonard and Madlyn Abramson Pediatric Research Center
Conference Room 123-ABC

Nikolaos Daskalakis, MD, PhD
Director, Neurogenomics and Translational Bioinformatics Laboratory, McLean Hospital
Assistant professor of Psychiatry, Harvard Medical School
Associate member, Stanley Center for Psychiatric Research at Broad Institute of MIT and Harvard

For more information, please contact: Nina Laney, Program Manager, Lifespan Brain Institute - CHOP at Laneyhl@email.chop.edu
Behavioral Health Opens New Intensive Outpatient Program

On January 6, 2020 Child and Adolescent Psychiatry and Behavioral Sciences opened a new intensive outpatient program for children and teens with eating disorders. The Eating Disorder Assessment and Treatment Intensive Outpatient Program (IOP) will be located at 3550 Market Street on the 2nd floor. Patients admitted to this program will attend sessions three times a week (Monday, Wednesday and Friday) in the afternoons. On average the length of treatment is anticipated to be six weeks. Treatment will be oriented towards group therapy skills building and family approaches to the treatment of eating disorders. Admission to the program will be after outpatient evaluation and determination of need. The program will serve children aged 10 to 18. Contact Amy Mack, Program Director with any questions. Contact (215) 590-0681 for patient referrals.

CHOP Psychiatry Joins NJ Transition to Adult Coordinated Care to Provide Telemedicine Visits

NJ Transition to Adult Coordinated Care (NJTACC), operating out of the CHOP Specialty Care Center, Princeton at Plainsboro, is designed to help families of patients with intellectual and developmental disabilities (ID/D) navigate the challenges related to changes in care during the teen and young adult years. The Telehealth Program of the Division of Community Care and Wellness of the Department of Child and Adolescent Psychiatry and Behavioral Services, with Lan Chi “Krysti” Vo as the Medical Director, and Robert Berkowitz as the TelePsychiatrist, are excited to collaborate with NJTACC to provide innovative video visits to patients at their convenient site of care. The Telehealth Program’s mission is facilitating and increasing access to high quality behavioral health services for children and adolescents through the use of telehealth modalities. For more information about the NJTACC program, including how to refer a patient, call 215-590-1295, email NJTACC@email.chop.edu, or visit this website.

Department of Psychiatry Call Center Triumph

What gets measured gets mastered. The Department of Psychiatry Center is proud to report a recent quality accomplishment. The team has been tracking a key metric called “Service Level in the Call Center” which is the percentage of calls answered within 30 seconds. The goal for the month of December was 80%. Ready for the good news? They exceeded that goal by answering 88% of calls within 30 seconds! The team celebrated with a Chik-Fil-A lunch! As an integral part of the patient experience, the call center team continues to provide quality care.

Keep the news coming!
Keep sending your content updates to us as they happen and we’ll be sure to include it in the next issue.

If you have news you’d like to share for consideration in the next newsletter, please contact: Ronald Andujar at 3535 Market Street, Philadelphia, Pennsylvania 19104.

Check out the new look of our website.